How investors are betting on innovation with pharma stocks

Cologne According to experts, the pharmaceutical industry is on the threshold of major development steps: ever more effective drugs for complex diseases are coming onto the market. One promising approval follows the next. This arouses the interest of investors.

“The industry is currently in an innovation cycle,” says Kristoffer Unterbruner, molecular biologist and portfolio manager at investment specialist Medical Strategy. “We are on the verge of a series of major breakthroughs.” The expert identifies three promising research areas. These three areas are also interesting for investors – as are the stocks of three companies, all of which are developing promising drugs.

Unterbruner counts Alzheimer’s research among the three promising research areas. According to him, the latest products from Eli Lilly and Biogen are likely to be blockbusters, i.e. drugs with annual sales of more than one billion US dollars.